TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12860500
Drug: Galantamine 16
Normalized name: galantamine 16 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 16 mg/d
Study: 12860497
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/d
Study: 15598477
Drug: Galantamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (all doses combined)
Study: 11903737
Drug: L-regimen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-regimen (30 mg lansoprazole u.i.d)
Study: 11903737
Drug: LC-regimen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-regimen (30 mg lansoprazole u.i.d. with 200 mg cetraxate q.i.d)
Study: 9215029
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 4 ml h-1
Study: 9215029
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 6 ml h-1
Study: 9215029
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 8 ml h-1
Study: 9215029
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 10 ml h-1
Study: 8356864
Drug: 2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg‐1 propofol
Study: 25743733
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (Control)
Study: 29067578
Drug: Transanal low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transanal low rectal dissection
Study: 29067578
Drug: Laparoscopic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic low rectal dissection
Study: 27532874
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone intervention for three months
Study: 22838094
Drug: OTC BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC BPO 5.5% formulation with lipohydroxy acid and tretinoin cream 0.025%
Study: 22838094
Drug: Prescription clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription clindamycin 1%-BPO 5% gel and tretinoin cream 0.025%
Study: 20542783
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (conservative group)
Study: 16225497
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg intravenous)
Study: 12373416
Drug: Flesinoxan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan 0.5 mg
Study: 12373416
Drug: Flesinoxan 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan 1 mg
Study: 10404500
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of ethanol (0.5 g.kg‐1)
Study: 8524562
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care by glaucoma-trained optometrists with reviews on a six monthly basis
Study: 2178961
Drug: Fenoterol 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 1.6 mg
Study: 6108129
Drug: Ketotifen (HC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (HC 20-511) 1 mg twice daily for 12 weeks
Study: 6108129
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily for 12 weeks
Study: 23794382
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 10 mg IV
Study: 20517223
Drug: Cytoflavin, 425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin, 425 mg, 2 tablets twice a day during 25 days
Study: 20517223
Drug: Aminalon, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminalon, 500 mg, 2 tablets 3 times a day during 25 days
Study: 10817549
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of rofecoxib once daily
Study: 10817549
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of rofecoxib once daily
Study: 10817549
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diclofenac 3 times daily
Study: 8803643
Drug: Captopril (C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (C 50 mg bid)
Study: 8803643
Drug: Ticlopidine (T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (T 250 mg bid)
Study: 1465278
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C + high-dose medroxyprogesterone acetate (MMPA)
Study: 26833461
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 125‐mg, 250‐mg, or 500‐mg AZM suppository
Study: 26833461
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of AZM 500‐mg tablet
Study: 25785316
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus before intubation, followed by 2 mg/kg/h continuous infusion)
Study: 25785316
Drug: Saline (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (same dosage as lidocaine)
Study: 18377121
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy only (CPT-C)
Study: 1908314
Drug: CC/hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/hMG
Study: 30999929
Drug: Namilumab 80
Normalized name: Namilumab
DrugBank: Namilumab (DB13037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab 80 mg
Study: 24930436
Drug: adapalene in
Normalized name: Product containing adapalene in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adapalene in combination with a moisturizer (heparinoid)
Study: 19473997
Drug: HSV suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV suppressive treatment (placebo-controlled)
Study: 3602020
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pirprofen twice daily
Study: 31576959
Drug: NSD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSD plus MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Study: 29921143
Drug: Mantram repetition
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mantram repetition therapy
Study: 27730819
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium nitrate treatment
Study: 23147874
Drug: Pressure Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure Volume Loop (PV-L) closure technique
Study: 17975151
Drug: 12-peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-peptide vaccine containing a mixture of 12 peptides from melanocytic differentiation proteins and cancer‐testis antigens
Study: 17975151
Drug: 4-peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-peptide vaccine with only melanocytic differentiation peptides
Study: 14727004
Drug: Ketamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.4 mg kg(‐1))
Study: 14727004
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg kg(‐1))
Study: 8153291
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 1-1.38 mg/kg/day for 21 days
Study: 8153291
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 3 mg/kg/day for 10 days
Study: 8153291
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 100 mg (1.38-1.85 mg/kg) daily for 21 days
Study: 12639652
Drug: Periprostatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic injection of 10 mL of 2% lidocaine solution without epinephrine
Study: 12639652
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL of 0.9% NaCl)
Study: 11189013
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin for up to 4 weeks
Study: 11189013
Drug: Metoprolol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (intravenous then oral) for up to 4 weeks
Study: 9202354
Drug: Right ventricle
Normalized name: Sus scrofa ventricle preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right ventricle to axillary patch configuration (12.7 +/- 5.9 J)
Study: 9202354
Drug: Right ventricle
Normalized name: Sus scrofa ventricle preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right ventricle to superior vena cava plus axillary patch configuration (9.8 +/- 5.2 J)
Study: 3963028
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg per day)
Study: 3963028
Drug: Aspirin (4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (4,000 mg per day)
Study: 30917364
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with intensive SBP goal < 120 mm Hg
Study: 30917364
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with standard SBP goal < 140 mm Hg
Study: 30917364
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy with intensive SBP goal < 120 mm Hg
Study: 30917364
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy with standard SBP goal < 140 mm Hg
Study: 24433061
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg/day) for 12 weeks
Study: 24433061
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor antagonists (ARBs)
Study: 10468987
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (0.036 U/kg/d)
Study: 7595856
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy at the anaerobic threshold (AT) level continued after discharge (group T)
Study: 7595856
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) with exercise therapy discontinued after discharge
Study: 2112480
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given in the overnight fasting state
Study: 2112480
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given 2 h after a carbohydrate-rich meal
Study: 23026438
Drug: Umeclidinium 125
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium 125 μg
Study: 25565796
Drug: Umeclidinium/vilanterol 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol 125/25 μg
Study: 15848529
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of MMF or AZA to 75% and then to 50% of the original dose at 4 months and 8 months after inclusion.
Study: 9024731
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) with nitroglycerin (NTG) infusion
Study: 9024731
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) infusion alone
Study: 2471718
Drug: SCH 434
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 434 (5 mg loratadine and 120 mg pseudoephedrine, administered twice daily)
Study: 26995988
Drug: Early chemoradiotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine
Study: 26995988
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiation therapy (historical control)
Study: 24132975
Drug: Methyl-d9-choline (22%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl-d9-choline (22% of total choline intake, 480 or 930 mg/d)
Study: 19745163
Drug: Inhibitor or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor or siRNA for endothelial NO synthase
Study: 16283367
Drug: HRT- (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT- (no hormone replacement therapy)
Study: 9077616
Drug: Chlorhexidine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.2% solution
Study: 3711377
Drug: Tar oil
Normalized name: Tar oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tar oil applied twice daily with ultraviolet B phototherapy
Study: 3711377
Drug: Oil vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil vehicle (an emollient) applied twice daily with ultraviolet B phototherapy
Study: 30572580
Drug: D-allulose at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-allulose at doses of 0.1 g/kg·BW to 1.0 g/kg·BW
Study: 30572580
Drug: D-allulose at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-allulose at 1.0 g/kg·BW
Study: 10399047
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy according to Beck
Study: 7554761
Drug: 99mTc‐DTPA (intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐DTPA (intra-arterial injection)
Study: 7554761
Drug: 99mTc‐DTPA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐DTPA (intravenous injection)
Study: 7554761
Drug: 99mTc‐HSA (intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐HSA (intra-arterial injection)
Study: 10216323
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of intravenous methylprednisolone
Study: 31743812
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) lipid emulsion, reduced to 0.4 g/kg daily
Study: 31743812
Drug: Olive/soybean (O/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive/soybean (O/S) lipid emulsion, reduced to 0.4 g/kg daily
Study: 24886392
Drug: Intervention includes
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention includes provision of kits with necessary medicines and laboratory supplies for ANC, a storage system, a tracking system, and training sessions for health care providers.
Study: 23206490
Drug: Intra-operative intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative intra-articular injection of magnesium sulphate and ropivacaine
Study: 8135721
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy alone
Study: 8135721
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy combined with desipramine
Study: 2674084
Drug: Intravenous polyclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin, 10 mCi (1 patient), 20 mCi (4 patients), or 30 mCi (2 patients)
Study: 2674084
Drug: Intravenous polyclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin
Study: 46959
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of yttrium-90 (irradiation)
Study: 30717707
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with high-dose radiotherapy (arms C + D)
Study: 30717707
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with standard-dose radiotherapy (arms A + B)
Study: 30717707
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with high-dose radiotherapy and nelfinavir (arms A + C)
Study: 30717707
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with standard-dose radiotherapy and nelfinavir (arms B + D)
Study: 25710876
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg) administered by inhalation 15 min before EVH
Study: 25710876
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by inhalation 15 min before EVH
Study: 19370171
Drug: Plitidepsin 7mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 7mg/m2 with L-carnitine (Arm B)
Study: 19370171
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of L-carnitine
Study: 11737438
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac gel in 2.5% hyaluronan gel
Study: 11737438
Drug: Inactive gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive gel vehicle (placebo)
Study: 9395759
Drug: Intravenous cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporine
Study: 9067953
Drug: Cyclosporine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (high doses)
Study: 9067953
Drug: Cyclosporine in
Normalized name: cyclosporine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine in combination with corticosteroids
Study: 342619
Drug: Influenza virus
Normalized name: Influenza virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza virus vaccine (A/New Jersey/76 [Hsw1N1]) from four different manufacturers
Study: 342619
Drug: Split‐product vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split‐product vaccine
Study: 342619
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four vaccines
Study: 342619
Drug: Split‐virus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split‐virus vaccine
Study: 30880442
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids (1 tablet/day)
Study: 29262509
Drug: Weitan Waifu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weitan Waifu patch
Study: 25143719
Drug: Testosterone-enanthate (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone-enanthate (125 mg/week)
Study: 22421906
Drug: 280 mg
Normalized name: levodopa 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg red wine polyphenols
Study: 22421906
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg red wine polyphenols
Study: 22421906
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of polyphenol treatment
Study: 2121359
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg, once daily)
Study: 2121359
Drug: L-acetylcarnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (500 mg, twice daily)
Study: 219491
Drug: beta-blocker
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker
Study: 219491
Drug: diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretic
Study: 219491
Drug: central antihypertensive
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: central antihypertensive agent
Study: 30981150
Drug: Experimental pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental pain induced by ultrasound‐guided injection of 1 mL hypertonic saline into the upper part of the right tibialis posterior muscle
Study: 23569144
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg GTW daily, orally for 52 weeks
Study: 23569144
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g 5-ASA daily, orally for 52 weeks
Study: 21332551
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (500 mg every 12 h)
Study: 21332551
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (2.0 g per day for 7 days)
Study: 19857627
Drug: Low-energy-density yogurt
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-density yogurt with inulin (6 g)
Study: 19857627
Drug: High-energy-density yogurt
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-density yogurt (440 kcal; 0.9 kcal/g)
Study: 19857627
Drug: Low-energy-density yogurt
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-density yogurt (180 kcal; 0.4 kcal/g)
Study: 16707864
Drug: 1% chloramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chloramine solution
Study: 16707864
Drug: 10% formalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% formalin solution
Study: 16707864
Drug: 0.02% thymol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% thymol solution
Study: 16707864
Drug: ‐20 degrees
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐20 degrees C (no storage solution)